Among 114,166 patients with type 2 diabetes and AF, a total of 23,467 new medication users were included in the cohort analysis (21,816 new users in the DPP4 inhibitor group and 1,616 new users in the SGLT2 inhibitor group). The gene discussed is DPP4; the disease is atrial fibrillation.